Onxeo Announces its Financial Agenda for 2019
Onxeo Announces its Financial Agenda for 2019
Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced its financial agenda for 2019.
Event |
Date* |
Full-year 2018 results |
Tuesday, March 12, 2019 |
Shareholders’ general meeting |
Friday, April 26, 2019 |
Half-year 2019 results |
Thursday, July 25, 2019 |
* This preliminary agenda may be modified. Press releases are published after financial markets close.